SEC Company Response from Cue Biopharma, Inc. (CUE) (CIK 0001645460) (CUE) — Dec 11, 2017
Cue Biopharma, Inc. (CUE) (CIK 0001645460)
Date: Dec. 11, 2017 · CIK: 0001645460 · Accession: 0001571049-17-008676
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-220550
Letter
VIA EDGAR CORRESPONDENCE Division of Corporation Finance Re: Cue Biopharma, Inc. Registration Statement on Form S-1 Filed September 21, 2017 File No. 333-220550
Dear Ms. Paik:
On behalf of Cue Biopharma, Inc. (the “Company”), we submit this letter providing a response to the comments raised by the Staff of the Securities and Exchange Commission (the “Staff”) on December 6, 2017 with respect to the Company’s registration statement on Form S-1 (File No. 333-220550) (the “Registration Statement”). Simultaneously with the filing of this letter, the Company is filing by EDGAR Amendment No. 4 to the Registration Statement (the “Registration Statement Amendment”) responding to the Staff’s comments as noted below. The bold type below is the Staff’s comments and the regular type constitutes the Company’s responses thereto.
Cover page
1. We note that you may extend the termination date beyond the initial offering period. Please expand your disclosure to indicate that if there are funds in escrow when you extend the offering period that these funds will be returned to subscribers who do not affirmatively reconfirm their subscription.
Revised disclosure responding to this comment has been added on the cover page and on page 12 of the Registration Statement Amendment.
Risk Factors
Concentration of ownership among our existing executive officers..., page 35
2. It appears you only have seven members on your board of directors, yet you state that three of the eight members of your board of directors are also employees of MDB. Please revise as appropriate to reconcile this discrepancy.
Revised disclosure responding to this comment is included on page 35.
U.S. Securities and Exchange Commission
December 11, 2017
Page 2
Business
Our Collaboration Agreement with Merck, page 55
3. We note your revisions to page 55 in response to our prior comment three. Please revise your disclosure to quantify the potential research and development, regulatory and commercial milestones separately.
Revised disclosure responding to this comment has been added on pages 56-57, 74 and F-49 of the Registration Statement Amendment.
Exhibits
4. Please file a complete copy of Exhibit 10.21, including all schedules and exhibits thereto. See Item 601(b)(10) of Regulation S-K.
Exhibit 10.21 has been refiled including the schedules and exhibits (of which there are none).
We appreciate your time and attention to the Company’s responses to the Staff’s comments. Should you have any questions, please call me at (704) 331-7440.
Very truly yours,
/s/ Mark Busch
Show Raw Text
CORRESP
1
filename1.htm
K&L
Gates LLP
Hearst
Tower, 47th Floor
214
North Tryon Street
Charlotte,
NC 28202
T +1 704 331 7400 F +1
704 331 7598
klgates.com
December 11,
2017
VIA EDGAR CORRESPONDENCE
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street N.E.
Washington, D.C. 20549
Attn: Irene Paik
Re: Cue Biopharma, Inc.
Registration Statement on Form S-1
Filed September 21, 2017
File No. 333-220550
Dear Ms. Paik:
On behalf of Cue Biopharma, Inc. (the “Company”),
we submit this letter providing a response to the comments raised by the Staff of the Securities and Exchange Commission (the “Staff”)
on December 6, 2017 with respect to the Company’s registration statement on Form S-1 (File No. 333-220550) (the “Registration
Statement”). Simultaneously with the filing of this letter, the Company is filing by EDGAR Amendment No. 4 to the Registration
Statement (the “Registration Statement Amendment”) responding to the Staff’s comments as noted below. The bold
type below is the Staff’s comments and the regular type constitutes the Company’s responses thereto.
Cover
page
1. We note that you may extend the termination date beyond the initial offering period. Please expand
your disclosure to indicate that if there are funds in escrow when you extend the offering period that these funds will be returned
to subscribers who do not affirmatively reconfirm their subscription.
Revised disclosure responding
to this comment has been added on the cover page and on page 12 of the Registration Statement Amendment.
Risk
Factors
Concentration
of ownership among our existing executive officers..., page 35
2. It appears you only have seven members on your board of directors, yet you state that three of
the eight members of your board of directors are also employees of MDB. Please revise as appropriate to reconcile this discrepancy.
Revised disclosure responding
to this comment is included on page 35.
U.S. Securities and Exchange Commission
December
11, 2017
Page 2
Business
Our Collaboration
Agreement with Merck, page 55
3. We note your revisions to page 55 in response to our prior comment three. Please revise your disclosure
to quantify the potential research and development, regulatory and commercial milestones separately.
Revised disclosure responding
to this comment has been added on pages 56-57, 74 and F-49 of the Registration Statement Amendment.
Exhibits
4. Please file a complete copy of Exhibit 10.21, including all schedules and exhibits thereto. See
Item 601(b)(10) of Regulation S-K.
Exhibit 10.21 has been
refiled including the schedules and exhibits (of which there are none).
We appreciate your time
and attention to the Company’s responses to the Staff’s comments. Should you have any questions, please call me at
(704) 331-7440.
Very truly yours,
/s/ Mark Busch
Mark Busch
cc: Daniel Passeri, Chief Executive Officer
Gary Schuman, Chief Financial
Officer